Linked Life Data

19929842

Source:http://linkedlifedata.com/resource/pubmed/id/19929842

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2010-3-10
pubmed:abstractText
Echinocandins are an interesting group of antifungals that were originally discovered in the early 1970s. They are a group of lipopeptides produced by fungi which consists of a large number of structural analogs of echinocandin B, the first echinocandin to be structurally characterized. All clinically used echinocandins are produced semi-synthetically. The cyclic peptide nuclear core is retained while the acyl chain is replaced to minimize toxicity and expand their spectrum of activity. It was not until 2002 with the introduction of caspofungin (Cancidas) into the clinics that their true worth was realized. Since the introduction of caspofungin, two other echinocandins, micafungin (Mycamine) and anidulafungin (Eraxis) have been introduced. They all function by inhibiting an enzyme unique for fungal cell wall production, which presumably accounts for their minimal side-effects. In this review, topics pertaining to their production, structural diversity, and use in the clinic along with the recent patents are discussed.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1574-891X
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
58-63
pubmed:dateRevised
2011-7-29
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Medical claims and current applications of the potent echinocandin antifungals.
pubmed:affiliation
Mississippi State University, Department of Biological Sciences and Department of Basic Sciences at the College of Veterinary Medicine, Mississippi State, Mississippi 39762, USA. jls859@msstate.edu
pubmed:publicationType
Journal Article, Review, Research Support, N.I.H., Extramural